Hypothesis

Tissue-specific CD38 activity, driven by local inflammatory signaling, creates a NAD+ consumption hotspot that overwhelms NAD+ precursor salvage, explaining why NR/NMN rescue fails in certain tissues.

Rationale

• Age-related rise in CD38 consumes NAD+ via ADPR cyclase activity (2).
• Inflammatory cytokines (e.g., IFNγ, TNFα) upregulate CD38 expression in macrophages and fibroblasts (2).
• Mitochondrial NAD+ depletion shifts lactate/pyruvate ratio, impairing SIRT3 activity and increasing ROS, which can further activate NF‑κB and CD38 transcription (1,4).
• This feed‑forward loop generates tissue‑specific NAD+ sinks that are not uniformly cleared by precursor supplementation alone.

Prediction

In aged mice, skeletal muscle will exhibit higher CD38 protein and activity than liver; combining a CD38 blocking agent (e.g., anti‑CD38 antibody) with NMN will normalize muscle NAD+ levels, lactate/pyruvate ratio, and mitochondrial respiration, whereas NMN alone will produce only modest changes; liver will show no added benefit from CD38 blockade.

Experimental Design

1. Use 24‑month‑old C57BL/6 mice; split into four groups (n=8 per group): vehicle, NMN (400 mg/kg/day i.p.), anti‑CD38 antibody (78 µg i.p. twice weekly), NMN + antibody.
2. After 4 weeks, harvest skeletal muscle (gastrocnemius) and liver.
3. Measure:
   • Total NAD+ and NADH by enzymatic cycling assay.
   • CD38 protein (Western blot) and activity (cADPR production).
   • Lactate and pyruvate concentrations; calculate lactate/pyruvate ratio (4).
   • Mitochondrial oxygen consumption (Seahorse) and ATP content.
   • SIRT3 acetylation of downstream targets (e.g., SOD2).
4. Statistical analysis: two‑way ANOVA (treatment × tissue) with post‑hoc Tukey.

Expected Outcomes

• NMN alone raises NAD+ modestly in both tissues but lactate/pyruvate ratio remains elevated in muscle.
• Antibody alone reduces CD38 activity without NAD+ change.
• Combination restores muscle NAD+ to young levels, normalizes lactate/pyruvate ratio, improves ATP and OCR, and reduces SIRT3‑target acetylation.
• Liver shows similar NAD+ increase with NMN but no further improvement with antibody, reflecting lower baseline CD38.

Potential Confounds

• Antibody may affect immune cell function; include flow cytometry to monitor macrophage infiltration.
• Compensatory upregulation of other NAD+ consumptases (e.g., PARPs, Sirtuins) could mask effects; measure PARP1 activity.

Falsifiability

If the combination fails to improve muscle lactate/pyruvate ratio or mitochondrial function beyond NMN alone, the hypothesis that tissue‑specific CD38 drives NAD+ sink is falsified. Conversely, if liver shows unexpected benefit from CD38 blockade, the premise of tissue‑specific CD38 dominance would need revision.